Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hematoma Expansion in Patients Diagnosed with Intracranial Hemorrhage on Mobile Stroke Unit
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
075

Assess rate of hematoma expansion (HE) among patient diagnosed with intracranial hemorrhage (ICH) on Mobile Stroke Unit (MSU).

Early HE is independently associated with poor functional outcomes and mortality in ICH patients. However, we lack data on HE rates within first 2 hrs from symptom onset. MSU provides a unique opportunity to track early ICH expansion.

Retrospective review of patients diagnosed with ICH on MSU from May 2018 to December 2019 was conducted. Patient demographics, Glasgow coma scale (GCS) were recorded. Hematoma volumes were tracked on head imaging obtained on MSU and after hospital admission. ABC/2 formula was used to calculate hematoma volumes. Intraventricular hemorrhage score (IVHS) was recorded.

17 patients were diagnosed with ICH on MSU. Mean age was 63 years, 77% male, and 82% black. 35% (n= 6) patient were diagnosed within 1 hr of symptom onset on MSU of whom 17% (1/6) had HE (20% ICH volume increase; IVHS decline by ≥2; GCS decline ≥ 2) between MSU and first hour imaging in emergency department (ED). 52% (n=9) were diagnosed with ICH within 2 hrs of symptom onset of whom 11% (2/9) had HE (ICH volume increase 11-20%, IVHS decline ≥ 2; GCS decline ≥ 2) between MSU and first hour imaging in ED. Overall, total expansion rate (early + late) was 33% for patients presenting within 1 hr and 22% within 2 hrs from symptom onset.

IVHS decline drives hematoma expansion in patients presenting within very early time window with ICH. Although limited by small sample size, our study provides an estimate of very early ICH expansion that have not been reported before. Analysis with large sample size by pooling data from different MSUs is recommended to confirm HE rates and correlation with functional outcome.

Authors/Disclosures
David Landzberg, MD
PRESENTER
Dr. Landzberg has nothing to disclose.
Srikant Rangaraju, MBBS (Emory University, Atlanta) Dr. Rangaraju has nothing to disclose.
Rajeel Imran, MD (Emory University School of Medicine) Dr. Imran has nothing to disclose.
Ashok Reddy Polu, MD (Fort Sanders Regional Medical Center) Dr. Polu has nothing to disclose.
Reema Choudhry, MD Dr. Butt has nothing to disclose.
Nicolas A. Bianchi, MD (Emory University) Dr. Bianchi has received personal compensation in the range of $0-$499 for serving as a Consultant for Innovation Hub Enterprises, LLC. The institution of Dr. Bianchi has received research support from Emory Medical Care Foundation.
No disclosure on file
Jonathan Ratcliff The institution of Dr. Ratcliff has received research support from Nico Corporation. The institution of Dr. Ratcliff has received research support from Sense .
Michael R. Frankel, MD (Emory Univ School of Med/Dept of Neuro) The institution of Dr. Frankel has received research support from Nico Corporation, Inc.
Digvijaya D. Navalkele, MD (Emory University) Dr. Navalkele has nothing to disclose.